          
|
|
Wednesday, February 3, 1999 Phase II Preclinical Study |
Next Previous Archive |
The Company is very pleased to announce that arrangements have been made to test the plasma samples from the Phase II macaque study of the Company's patented monoclonal antibody 1F7 (mAb 1F7). These tests of the biological efficacy of antiviral immunity induced or restored by mAb 1F7 will use a highly sensitive polymerase chain reaction-based assay to determine the viral load in plasma samples from SHIV-infected monkeys.
Arrangements for these tests were made by Immpheron, Inc., the Company's research partner on the project, through a collaboration with researchers at Harvard University. This collaboration will enable the plasma tests to be performed at the United States National Cancer Institute laboratory, part of the National Institute of Health.
The Phase II study involved nine macaques, which are a recognized model of HIV disease in humans, observed over a period of over six months and treated with two series of injections with mAb 1F7. Results of the tests are to form part of the Company's intended application to the FDA for a clinical trial of mAb 1F7 as an Investigational New Drug.
In a related study, research has commenced on lymph node samples from selected macaques in collaboration with researchers at Duke University Medical Centre. This study will investigate B-cell response to mAb 1F7. In the Phase I macaque study mAb 1F7 appeared to strengthen the immune response and may play a role by inducing the immune system to produce antibodies of different specificity.
Research is ongoing into the mechanism of the patented mAb 1F7 through an evaluation of the virus neutralizing antibody levels observed in the earlier Phase I macaque study. A manuscript by Dr. Sybille Müller, Vice President of Immpheron and Director of the Company's research program, has been submitted to a recognized journal in the field of immunology and AIDS.
On corporate matters, the Company has received regulatory approval for the private placement of $54,000 and the issue of 360,000 shares together with one year warrants for the purchase of an additional 180,000 shares all at a price of $0.15 per share. The Company concluded its arrangement with an investor relations firm at the end of last year.
"signed" The Vancouver Stock Exchange has not reviewed and does not accept responsibility for the adequacy or the accuracy of this release. For more information, please contact |
|||
|
